Urologix adds Smrdel to management team
This article was originally published in Clinica
Brian Smrdel has become the CFO of Urologix, a firm that specialises in minimally-invasive technology for treating benign prostatic hyperplasia. Mr Smrdel was most recently the corporate controller at Angeion, a developer of cardiorespiratory diagnostic systems. Prior to this, he worked in various financial roles at PepsiAmericas, co-operative firm Land O’Lakes and retailing company Target. Rebecca Weber will continue as Urologix’s director of finance. Since 2008, she has been working as both the firm’s controller and director of finance. Urologix’s lead product is the Targis system, which uses “cooled thermotherapy” (transurethral microwave thermotherapy) to deliver targeted microwave energy deep into hyperplastic prostate tissue, creating coagulative necrosis.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals